Sarepta's Q2 Profitability Masked a 34% Revenue Drop-Why That Keeps SRPT Risky

Profitability held up, but the revenue decline still drives the story

Sarepta's second quarter created a clear tension for investors. The company delivered GAAP operating income of $13.3 million and $86.5 million in non-GAAP operating income, even as revenue fell. That is notable because it is the first quarterly read under new CEO Michael Severino, who took over on July 28.

Operating profit does not cancel a weaker sales base

Q2 also included $328.7 million of net product revenue, made up of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue. That shows the business still has a real commercial base and can still produce profitability.

Still, profitability alone does not settle the story. When the top line is weakening, operating income mainly shows that the cost base has not yet adjusted to a smaller revenue base. For SRPT, the more important question is whether leadership can stabilize demand before investors lose patience with the slowdown.

Guidance points to a slower second half, not an immediate recovery

The key debate is no longer whether Sarepta was profitable in Q2. It is what the sales outlook says about the next few quarters.

Management narrowed the 2026 outlook

Management narrowed its 2026 net product revenue guidance to $1.2 billion–$1.3 billion and said second-half revenue expected to be modestly below the first half. It also said ELEVIDYS revenue was likely to be lower in the third quarter. Taken together, that points to continued pressure on the revenue base rather than an immediate reset.

ELEVIDYS enrollment is improving, but the revenue lag still matters

Sarepta said ELEVIDYS enrollment-form activity improved sequentially, along with more engagement from returning sites and interest from new referral sites. But management also said those improvements may contribute more meaningfully to revenue in 2027 because of an approximately six-month enrollment-to-infusion timeline. In other words, commercial momentum may be improving before the sales data fully reflects that improvement.

The bull case and bear case are really about timing

Bull case: 2026 is a bridge year while the funnel improves

If ELEVIDYS enrollment activity keeps improving, this year may look more like a timing reset than a broken franchise. The balance sheet gives Sarepta room to wait for that conversion. The company ended the quarter with approximately $945.0 million of cash, cash equivalents, restricted cash and investments, up about $197.0 million during Q2.

There is also a broader pipeline case. Investors still have second-half 2026 interim MAD-study data for SRP-1001 and SRP-1003, with early Huntington's disease proof-of-biology data expected in early 2027. If ELEVIDYS eventually tracks back toward expectations and the pipeline adds new proof points, the earnings outlook could steepen from here.

Bear case: the guidance already reflects weaker demand

Skeptics will focus on what the outlook openly admits. When a company says the second half should be modestly below the first half and ELEVIDYS revenue should be lower in the third quarter, the market has to price in a recovery, not just clean execution.

That makes each quarter harder to underwrite. Sarepta now faces a Duchenne market with four approved Duchenne therapies, which can affect referral patterns, slow new-patient uptake, and increase quarter-to-quarter volatility.

The bear case is not that Sarepta suddenly faces a cash crisis. It is that the franchise may be weakening just enough to turn a once-clear growth story into a longer rebuild.

What would change the market's view quickly

Investors do not need to solve the whole thesis today. They need evidence that improving enrollment activity is converting into actual shipments and repeatable uptake.

The cleanest watchpoints are: - whether ELEVIDYS enrollment improvements start showing up in third- and fourth-quarter revenue - whether the company can keep execution disciplined while the enrollment-to-infusion lag works through - whether pipeline or regulatory progress broadens the story beyond one product cycle

One useful signpost is regulatory motion on the PMO platform. The FDA has accepted supplemental applications for AMONDYS 45 and VYONDYS 53 seeking conversion from accelerated to traditional approval, with a target action date of February 28, 2027.

Cash protects the balance sheet, but revenue conversion still drives the stock

Sarepta's financial cushion is important because it removes the immediate liquidity question. The company still has about $945.0 million of cash, cash equivalents, restricted cash and investments, up about $197.0 million for the quarter.

The raised collaboration and other revenue guidance to $550 million-$600 million also helps credibility, but investors should read it in context. Management attributed much of that increase to higher Roche contract-manufacturing revenue, which supports the numbers without solving the core Duchenne uptake question.

For now, the setup is straightforward: cash keeps SRPT in the game, but only repeatable product uptake and clearer revenue conversion should meaningfully re-rate the stock.